LEXICON PHARMACEUTICALS INC (LXRX) Stock News

USA - NASDAQ:LXRX - US5288723027 - Common Stock

1.505 USD

-0.06 (-3.53%)

Last: 11/12/2025, 12:49:43 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

LXRX Latest News, Press Relases and Analysis

All

Press Releases

6 days ago - By: Chartmill

News Image

Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) Q3 2025 Earnings Surpass Expectations, Fueling Pre-Market Rally

a day ago - By: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals to Participate at the Jefferies 2025 London Healthcare Conference

a day ago - By: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals to Participate at the Jefferies 2025 London Healthcare Conference

4 days ago - By: Lexicon Pharmaceuticals, Inc.

Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025

4 days ago - By: Lexicon Pharmaceuticals, Inc.

Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025

6 days ago - By: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides R&D Updates

6 days ago - By: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides R&D Updates

6 days ago - By: Benzinga - Mentions: STVN PODD AMRK SOLV ...

Earnings Scheduled For November 6, 2025

7 days ago - By: Zacks Investment Research - Mentions: DNTH

Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Lags Revenue Estimates

8 days ago - By: Lexicon Pharmaceuticals, Inc.

Data Demonstrating Unique Benefits of Sotagliflozin in Diverse Patient Populations will be Presented at the Hypertrophic Cardiomyopathy Society and American Heart Association’s Sessions 2025 in New Orleans

8 days ago - By: Lexicon Pharmaceuticals, Inc.

Data Demonstrating Unique Benefits of Sotagliflozin in Diverse Patient Populations will be Presented at the Hypertrophic Cardiomyopathy Society and American Heart Association’s Sessions 2025 in New Orleans

13 days ago - By: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025

13 days ago - By: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025

a month ago - By: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit

a month ago - By: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain

a month ago - By: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain

2 months ago - By: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes

2 months ago - By: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes

2 months ago - By: Lexicon Pharmaceuticals, Inc.

Pilavapadin Provides Meaningful Pain Reduction in Adults with Diabetic Peripheral Neuropathic Pain (DPNP) in Data Presented at the European Association for the Study of Diabetes (EASD) and NEUROdiab Annual Meetings

2 months ago - By: Lexicon Pharmaceuticals, Inc.

Pilavapadin Provides Meaningful Pain Reduction in Adults with Diabetic Peripheral Neuropathic Pain (DPNP) in Data Presented at the European Association for the Study of Diabetes (EASD) and NEUROdiab Annual Meetings

2 months ago - By: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals to Present Additional Clinical Data on Pilavapadin at Three Upcoming Medical Meetings

2 months ago - By: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals to Present Additional Clinical Data on Pilavapadin at Three Upcoming Medical Meetings

2 months ago - By: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals Announces Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes

2 months ago - By: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals Announces Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes

2 months ago - By: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals to Present New Preclinical Data on Pilavapadin in Chemotherapy-Induced Pain and Multiple Sclerosis Pain at NeuPSIG 2025

2 months ago - By: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals to Present New Preclinical Data on Pilavapadin in Chemotherapy-Induced Pain and Multiple Sclerosis Pain at NeuPSIG 2025

2 months ago - By: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals Announces Presentation of Diabetic Peripheral Neuropathic Pain Patient Insights at PAINWeek 2025

2 months ago - By: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals Announces Presentation of Diabetic Peripheral Neuropathic Pain Patient Insights at PAINWeek 2025

2 months ago - By: Lexicon Pharmaceuticals, Inc.

Sotagliflozin Provides Consistent Relative Risk Reduction in Heart Failure and Major Cardiovascular Events Across All Age Ranges, Including Greater Than 75, in Data Presented at the European Society of Cardiology (ESC) 2025 Congress

3 months ago - By: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals to Participate at Two Upcoming Investor Conferences

3 months ago - By: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals to Participate at Two Upcoming Investor Conferences

3 months ago - By: Zacks Investment Research

Lexicon (LXRX) Upgraded to Buy: Here's What You Should Know

3 months ago - By: The Motley Fool

Lexicon (LXRX) Q2 Revenue Soars 1,706%

3 months ago - By: Zacks Investment Research - Mentions: OCS

Lexicon Pharmaceuticals (LXRX) Q2 Earnings and Revenues Top Estimates

3 months ago - By: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates

3 months ago - By: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates

3 months ago - By: Benzinga - Mentions: OEC VTLE DIN INSE ...

Earnings Scheduled For August 6, 2025

3 months ago - By: Zacks Investment Research - Mentions: SUPN

Supernus Pharmaceuticals (SUPN) Surpasses Q2 Earnings and Revenue Estimates